Loxo and Illumina in partnership over diagnostic for cancer drug

April 10 (Reuters) - Loxo Oncology is partnering with genetic testing company Illumina Inc to use Illumina's diagnostic tool alongside larotrectinib, the drug developer's potential blockbuster drug, the companies said on Tuesday.